Pfizer Inc (PFE)
24 Oct 2014
|Market Cap (Mil.):||$181,348.70|
|Shares Outstanding (Mil.):||6,340.86|
Oct 24 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:
* EMA also backs new drugs from Pfizer, Baxter, Clinuvel (Adds AstraZeneca comment, further details)
LONDON/NEW YORK - U.S. drugmaker Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca.
Oct 23 - Pfizer Inc on Thursday said its board of directors has authorized an $11 billion share repurchase program to be utilized over time.
- A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.
Oct 23 - A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.
* Governments or multilateral agencies may offer indemnity
- Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.
Oct 16 - Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.
Oct 16 - Pfizer Inc failed in its attempt to remove a black box warning from its controversial quit-smoking drug, Chantix, after an advisory panel to the U.S. Food and Drug Administration voted against the removal.
|Johnson & Johnson (JNJ.N)||$103.13||+0.50|
|Novartis AG (NOVN.VX)||CHF85.75||+0.35|
|Merck & Co., Inc. (MRK.N)||$57.61||+0.98|
|Roche Holding Ltd. (ROG.VX)||CHF278.00||-1.40|
|Abbott Laboratories (ABT.N)||$42.46||+0.03|
|Bayer AG (BAYGn.DE)||€95.41||-2.28|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€84.60||-0.30|
|AstraZeneca plc (AZN.L)||4,327.50p||-7.00|
|GlaxoSmithKline plc (GSK.L)||1,415.50p||+3.50|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of PFIZER INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
"The Economy Matters" Report for PFE: the economy's impact on PFE's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.